Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
I
175250
vs
K
KOSPI 200
Over the past 12 months, Icure Pharmaceutical Inc has underperformed KOSPI 200, delivering a return of 0% compared to KOSPI 200's +50% growth.
Stocks Performance
175250 vs KOSPI 200
Performance Gap
175250 vs KOSPI 200
Performance By Year
175250 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Icure Pharmaceutical Inc
Glance View
Icure Pharmaceutical Inc. engages in the development and manufacture of transdermal drug delivery system. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-07-12. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances. The cosmetics are sold under the names of Botalinum, Mediheal N.M.F, Meditime, among others. The Pharmaceutical segment is engaged in the manufacturing and sale of over the counter (OTC) drugs, ethical the counter (ETC) drugs, as well as quasi drugs. The OTC drugs include anti-inflammatory analgesics and dementia treatments. The firm distributes its products within the domestic market and to overseas markets.